Update on thalassemia treatment in taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects

Hemoglobin

Volumn 33, Issue 5, 2009, Pages 304-311

  Peng, Ching Tien ^a,b   Chang, Jeng Sheng ^a   Wang, Lin Yen ^c   Chiou, Shyh Shin ^d   Hsiao, Chih Cheng ^e   Wang, Shih Chung ^f   Hung, Giun Yi ^g   Wu, Kang His ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b ASIA UNIVERSITY   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cardiomyopathy; Guideline; Hematopoietic stem cell transplantation (HSCT); Iron chelator; Taiwan; Thalassemia

Indexed keywords

CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ALOPECIA; BETA THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORD BLOOD STEM CELL TRANSPLANTATION; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENTIATION; DRUG SAFETY; EVENT FREE SURVIVAL; FERRITIN BLOOD LEVEL; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; IRON OVERLOAD; LIFE EXPECTANCY; NATIONAL HEALTH INSURANCE; SIDE EFFECT; SIDEROSIS; SURVIVAL RATE; TAIWAN; THALASSEMIA MAJOR; TREATMENT OUTCOME;

BENZOIC ACIDS; BETA-THALASSEMIA; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; CHELATION THERAPY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEFEROXAMINE; FERRITINS; GUIDELINES AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON CHELATING AGENTS; PYRIDONES; SIDEROPHORES; SIDEROSIS; TAIWAN; TREATMENT OUTCOME; TRIAZOLES;

EID: 70350642088     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903212969     Document Type: Conference Paper

References (14)

1. Peng CT, Wu JY, Tsai Ch, et al. Molecular diagnosis of patients with b-thalassemia major in central Taiwan by amplified created restriction site analysis. J Hum Genet. 1998;43(4):237-241.
2. Lin KH, Lin KS. Results of therapy for b-thalassemia major. J Formos Med Assoc. 1992;91(2):126-130.
3. Wu KH, Chang JS, Su BH, Peng CT. Tricuspid regurgitation in patients with b-thalassemia major. Ann Hematol. 2004;83(12):779-783.
4. Wu KH, Chang JG, Ho YJ, et al. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with b-thalassemia major. Hemoglobin. 2006; 30(2):251-256.
5. Peng CT, Chow KC, Chen JH, et al. Safety monitoring of cardiac and hepatic systems in b-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003;70(6):392-397.
6. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regress severe heart failure in patients with b-thalassemia major. Ann Hematol. 2004;83(7):471-473.
7. Huang YC, Chang CS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from deferoxamine to deferiprone in b-thalassemia major patients. Hemoglobin. 2006;30(2):229-238.
8. Peng CT, Wu KH, Wu SF, et al. Deferiprone or deferoxamine versus combination therapy in patients with b-thalassemia major: a case study in Taiwan. Hemoglobin. 2006;30(1):125-130.
9. Peng CT, Tsai CH, Wu KH. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience. Hemoglobin. 2008;32(1-2):49-62.
10. Peng CT, Chang JS, Wu KH, et al. Mechanism of and obstacles to iron cardiomyopathy in thalassemia. Front Biosci. 2008;13(1):5975-5987.
11. Lin KH, Lin KS. Allogeneic bone marrow transplantation for thalassemia in Taiwan: factors associated with graft failure. Am J Pediatr Hematol Oncol. 1989;11(4):417-423.
12. Jaing TH, Wang B, Gjertson D, et al. Unrelated cord blood transplantation for transfusion-dependent thalassemia a CIBMTR audited retrospective analysis of 30 consecutive patients from a single center (abstract 131). Blood. 2008;112:3885.
13. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-355.
14. Kontoghiorghes GJ, Eracleous E, Economides Ch, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chlelators ICL670, GT56-252, L1NAII and their combinations. Curr Med Chem. 2005;12(23):2663-2681.